Proactive Investors - Run By Investors For Investors

Rhinomed registers Pronto vapour release technology as a class-one medical device with both US and Australian regulators

The new Pronto range of dual action products is set to go on sale in the second half of this year.
Rhinomed registers Pronto vapour release technology as a class-one medical device with both US and Australian regulators
When the Pronto device is stored in its case in the recharge position, the device is replenished with essential oil formulation ready for reuse

Rhinomed Ltd (ASX:RNO) has registered its revolutionary new Pronto rechargeable vapour release technology with both the US Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) as a class-one medical device.

In the US, Rhinomed has now completed registration of Pronto covering both variants – Pronto Sleep and Pronto Clear – as a class-one medical device with the FDA.

The company also confirmed registration of Pronto as a class-one medical device with the TGA in Australia, using Rhinomed’s existing TGA listing under the same product category as its Mute and Turbine products.

Shares increased up to 16% to 25 cents.

READ: Rhinomed to launch vapour release technology after securing US purchase orders

The new Pronto OTC range includes the novel Airstream release systems, which allows the continuous release of an essential oil blend into the nasal airstream over a set period.

By combining this new vapour release technology with the Mute’s stenting action, Rhinomed provides users with a unique dual action device that not only improves nasal airflow but delivers a soothing blend of essential oils to help clear a stuffy nose.

Pronto also includes a novel recharging and storage case that allows Pronto to be recharged before each use.

 

 

The company is completing production and will be shipping the new products at the end of May and confirms that both products will be sold online through select retail partners.

View full RNO profile View Profile

Rhinomed Ltd Timeline

Newswire
March 13 2017

Related Articles

cancer
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
salmon
Tue
Long-term fundamentals remain firmly in the seafood specialist's favour
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use